Holen Sie sich die Stockscreener-App
1.17
4.46%
0.05
Hcw Biologics Inc Aktie (HCWB) Neueste Nachrichten
HCW Biologics Announces Special Meeting for Stockholder Vote on Warrant Issuance Linked to July 2026 Private Placement - Kalkine Media
HCW Biologics Announces Strategic $1.5 Million Financing - TipRanks
HCW Biologics Prices $1.5 Million Private Placement With Existing Stockholder - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Private Placement - GlobeNewswire
Clinical trials and drug studies are among the planned uses for proceeds from HCW Biologics' $1.5 million deal. - Stock Titan
HCW Biologics Board Withdraws Performance Equity Plan Proposal After Stockholder Feedback - minichart.com.sg
HCW Biologics Updates Special Meeting Proxy Materials - TipRanks
HCW Biologics removes equity-plan proposal, reschedules special meeting - TradingView
HCW Biologics (HCWB) asks holders to lift warrant share cap - Stock Titan
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
HCW Biologics signs global HCW11-006 distribution deal - TipRanks
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Yahoo Finance
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com Canada
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com India
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - stockstotrade.com
HCW Biologics signs distribution deal with Akron Biotech - Investing.com
HCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech for HCW11-006 Reagent Commercialization - Quiver Quantitative
A reagent may help make longer-lasting immune cells. HCW Biologics will supply it to Akron. - Stock Titan
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
HCW Biologics (NASDAQ: HCWB) asks investors to vote on more equity than its current share count - Stock Titan
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Investing News Network
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - The Manila Times
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - GlobeNewswire
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceInstitutional Flow Picks - dars.gov.et
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Nigeria
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com India
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com UK
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusInvestment Factor - dars.gov.et
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - The Manila Times
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusBollinger Squeeze - dars.gov.et
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Australia
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):